Cargando…

Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling

Colitis-associated cancer (CAC) is a subtype of inflammatory bowel disease (IBD)-associated colorectal cancer. Huoxiang Zhengqi (HXZQ) is a classical Chinese herbal medicine and has been used to treat intestinal disorders, however, anti-CAC effects and underlying mechanisms of HXZQ have not been rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Mingyuan, Liu, Honghan, Cao, Tianjiao, Li, Lanzhou, Sun, Zhen, Qiu, Ye, Wang, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634060/
https://www.ncbi.nlm.nih.gov/pubmed/36339623
http://dx.doi.org/10.3389/fphar.2022.1002269
_version_ 1784824383973359616
author Dong, Mingyuan
Liu, Honghan
Cao, Tianjiao
Li, Lanzhou
Sun, Zhen
Qiu, Ye
Wang, Di
author_facet Dong, Mingyuan
Liu, Honghan
Cao, Tianjiao
Li, Lanzhou
Sun, Zhen
Qiu, Ye
Wang, Di
author_sort Dong, Mingyuan
collection PubMed
description Colitis-associated cancer (CAC) is a subtype of inflammatory bowel disease (IBD)-associated colorectal cancer. Huoxiang Zhengqi (HXZQ) is a classical Chinese herbal medicine and has been used to treat intestinal disorders, however, anti-CAC effects and underlying mechanisms of HXZQ have not been reported. An azoxymethane/dextran sulfate sodium-induced CAC mice model was used to investigate the anti-CAC effect of HXZQ. HXZQ significantly reduced colonic inflammation, suppressed the size and number of tumors, and reduced the levels of pro-inflammatory cytokines (interleukin [IL]-1α, IL-1β, IL-6, IL-17A, IL-21, IL-23, granulocyte macrophage-colony stimulating factor, and tumor necrosis factor-α) and oxidative stress markers (reactive oxygen species and malondialdehyde), and increased the levels of anti-inflammatory cytokines (IL-10 and IL-27) in CAC mice. Intestinal microbiota and serum metabolomics analyses indicated that HXZQ altered the gut microbial composition and the abundance of 29 serum metabolites in CAC mice. Additionally, HXZQ activated the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) signaling pathway and increased the levels of antioxidants such as catalase (CAT), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductases-1 (NQO-1), and superoxide dismutase-1 (SOD-1). HXZQ inhibited the activation of the nuclear factor kappa-B (NF-κB) signaling pathway and decreased the expression of NLR family pyrin domain containing 3 (NLRP3) by inhibiting the phosphorylation of inhibitor of nuclear factor kappa-B (IκB), inhibitor of nuclear factor kappa-B kinase (IKK), and NF-κB. In conclusion, HXZQ alleviated CAC in mice by modulating the intestinal microbiota and metabolism, activating Nrf2-mediated antioxidant response, and inhibiting NF-κB-mediated NLRP3 inflammasome activation against inflammation. The present data provide a reference for the use of HXZQ as a therapeutic or combination agent for clinical CAC treatment.
format Online
Article
Text
id pubmed-9634060
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96340602022-11-05 Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling Dong, Mingyuan Liu, Honghan Cao, Tianjiao Li, Lanzhou Sun, Zhen Qiu, Ye Wang, Di Front Pharmacol Pharmacology Colitis-associated cancer (CAC) is a subtype of inflammatory bowel disease (IBD)-associated colorectal cancer. Huoxiang Zhengqi (HXZQ) is a classical Chinese herbal medicine and has been used to treat intestinal disorders, however, anti-CAC effects and underlying mechanisms of HXZQ have not been reported. An azoxymethane/dextran sulfate sodium-induced CAC mice model was used to investigate the anti-CAC effect of HXZQ. HXZQ significantly reduced colonic inflammation, suppressed the size and number of tumors, and reduced the levels of pro-inflammatory cytokines (interleukin [IL]-1α, IL-1β, IL-6, IL-17A, IL-21, IL-23, granulocyte macrophage-colony stimulating factor, and tumor necrosis factor-α) and oxidative stress markers (reactive oxygen species and malondialdehyde), and increased the levels of anti-inflammatory cytokines (IL-10 and IL-27) in CAC mice. Intestinal microbiota and serum metabolomics analyses indicated that HXZQ altered the gut microbial composition and the abundance of 29 serum metabolites in CAC mice. Additionally, HXZQ activated the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) signaling pathway and increased the levels of antioxidants such as catalase (CAT), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductases-1 (NQO-1), and superoxide dismutase-1 (SOD-1). HXZQ inhibited the activation of the nuclear factor kappa-B (NF-κB) signaling pathway and decreased the expression of NLR family pyrin domain containing 3 (NLRP3) by inhibiting the phosphorylation of inhibitor of nuclear factor kappa-B (IκB), inhibitor of nuclear factor kappa-B kinase (IKK), and NF-κB. In conclusion, HXZQ alleviated CAC in mice by modulating the intestinal microbiota and metabolism, activating Nrf2-mediated antioxidant response, and inhibiting NF-κB-mediated NLRP3 inflammasome activation against inflammation. The present data provide a reference for the use of HXZQ as a therapeutic or combination agent for clinical CAC treatment. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9634060/ /pubmed/36339623 http://dx.doi.org/10.3389/fphar.2022.1002269 Text en Copyright © 2022 Dong, Liu, Cao, Li, Sun, Qiu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dong, Mingyuan
Liu, Honghan
Cao, Tianjiao
Li, Lanzhou
Sun, Zhen
Qiu, Ye
Wang, Di
Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title_full Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title_fullStr Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title_full_unstemmed Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title_short Huoxiang Zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating Nrf2/NF-κB/NLRP3 signaling
title_sort huoxiang zhengqi alleviates azoxymethane/dextran sulfate sodium-induced colitis-associated cancer by regulating nrf2/nf-κb/nlrp3 signaling
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634060/
https://www.ncbi.nlm.nih.gov/pubmed/36339623
http://dx.doi.org/10.3389/fphar.2022.1002269
work_keys_str_mv AT dongmingyuan huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT liuhonghan huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT caotianjiao huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT lilanzhou huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT sunzhen huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT qiuye huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling
AT wangdi huoxiangzhengqialleviatesazoxymethanedextransulfatesodiuminducedcolitisassociatedcancerbyregulatingnrf2nfkbnlrp3signaling